Early Cure Pharmacy Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 13 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -10.99%
- Profit Growth -28.91%
- Ebitda 14.32%
- Net Worth -200.18%
- Total Assets 28.96%
About Early Cure Pharmacy
Early Cure Pharmacy Private Limited (ECPPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 December 2011 and has a history of 13 years and one month. Its registered office is in Delhi, India.
The Corporate was formerly known as Relief Retails Prvate Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Neeraj Garg, Sangita Devi, and Harishchandra Kumar serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U52100DL2011PTC229074
-
Company No.
229074
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
21 Dec 2011
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
What products or services does Early Cure Pharmacy Private Limited offer?
Early Cure Pharmacy Private Limited offers a wide range of products and services, including Flavours & Aromatics, Dry Powder Flavours.
Who are the key members and board of directors at Early Cure Pharmacy?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neeraj Garg
|
Director | 31-Jan-2017 | Current |
|
Sangita Devi
|
Director | 27-Dec-2021 | Current |
|
Harishchandra Kumar
|
Director | 27-Dec-2021 | Current |
Financial Performance of Early Cure Pharmacy.
Early Cure Pharmacy Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 10.99% decrease. The company also saw a substantial fall in profitability, with a 28.91% decrease in profit. The company's net worth observed a substantial decline by a decrease of 200.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Early Cure Pharmacy?
In 2017, Early Cure Pharmacy had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Enze Dreams Private LimitedNeeraj Garg is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Early Cure Pharmacy?
Unlock and access historical data on people associated with Early Cure Pharmacy, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Early Cure Pharmacy, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Early Cure Pharmacy's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
